BenevolentAI
a now approved covid treatment that reduces mortality by covid drug cation custom work human guided iterative queries of knowledge graph computational tools enabled scientists to explore the information in the graph a number of suitable approved drugs through interactive and visual presentations of data an approved rheumatoid arthritis drug as the candidate in just hours uncovered previously unknown anti viral properties our technology was able to extract and infer new information about combined anti viral and anti in mechanism of action research published in in novel our tech a novel antiviral mechanism from published research data using our proprietary and engineering frameworks rapid introspection tools empowered scientists to rapidly explore and evaluate possible biological narratives access hypotheses in just effective is the most effective treatment proven to reduce mortality from covid in control trials barrier trial showed reduces mortality by across all patients and by in ventilated or patients world first of studies using to predict drugs to treat covid ours is the only one to be clinically approved now approved as a treatment in the us japan identified | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
29 of 42
Related slides by other companies
ATAI
Investor Day
January 2022
why are there no approved treatments for | ATAI
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io